Bavarian Nordic is developing an MVA-BN® based HIV vaccine for prophylactic and therapeutic use:
MVA-BN® multiantigen is an MVA-BN® vaccine expressing eight whole or truncated antigens from the HIV virus with the aim of eliciting a very broad immune response against HIV. MVA-BN® multiantigen is under development as a prophylactic and therapeutic HIV vaccine and is currently in the preclinical phase.
